Q3 2023 U.S. Commercial Highlights

Total Q3 2023 U.S. net revenue of $4.1 million

Prescriptions for Q3 2023 increased 76% sequentially, exceeding 54,000 for the first nine months of 2023

London, UK, 07 December, 2023: Shield Therapeutics plc (LSE: STX, "Shield"), a commercial stage pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated specialty pharmaceutical product, to address a significant unmet medical need for patients suffering from iron deficiency (with or without anemia) today summarizes key highlights of the Q3 2023 U.S. commercialization for Accrufer®, including total prescriptions of more than 54,000 for the first nine months of 2023, and 76% sequential quarterly growth in prescriptions to over 27,750, for Q3 2023.

Key Q3 Results (all percent comparisons are sequential to Q2 2023 unless otherwise indicated)

• Total Prescriptions -- Over 27,750, increased 76%
• Average Net Selling Price - Increase of 24% to $148/prescription compared to H1 2023
• Revenue - U.S. Q3 net revenue of $4.1MM (unaudited)
• New Prescriptions - increased 87%
• First time writers -- increased 27%
• Repeat Writers - 77% of the HCP's who wrote an Rx in Q3 2023 had also written one in Q2 2023

Greg Madison, CEO of Shield Therapeutics, commented: "Shield continues to make excellent progress on the U.S. commercial launch of Accrufer®. As we approach the one-year anniversary of the announcement of the Viatris agreement, I am pleased to report that the collaboration continues to deliver excellent results, based on the stand-out performance of the combined commercial team, which has produced consistent and strong sequential prescription growth and key performance indicators (KPI), which are trending towards previous guidance. In addition, we have made positive strides towards our goal of increasing our average net selling price and expect further progress in 2024.

"Reflecting on our year-to-date performance, I am proud to share that we continue to stay focused on our goal of making Accrufer® the "oral iron of choice" and a trusted brand for patients and providers in the U.S. and beyond," continued Mr. Madison. "We are building a strong and dedicated team, underscored by the recent addition of our Vice President of Marketing, Emily Bulat, and continue our progress towards the recruitment of a new Chief Financial Officer. I remain very optimistic about the growth prospects for Accrufer® as we look ahead to 2024."

Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the U.S. and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, Accrufer® has the potential to meet an important unmet medical need for both physicians and patients.